Ascendis Pharma A/S’s (ASND) Overweight Rating Reaffirmed at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga reports. They presently have a $170.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 18.89% from the stock’s previous close.

A number of other equities analysts have also recently weighed in on ASND. The Goldman Sachs Group upped their price objective on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. Bank of America increased their price target on Ascendis Pharma A/S from $165.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Thursday, September 5th. Oppenheimer upgraded Ascendis Pharma A/S from a “market perform” rating to an “outperform” rating and set a $180.00 target price for the company in a research note on Thursday, September 5th. Finally, Stifel Nicolaus began coverage on shares of Ascendis Pharma A/S in a research note on Friday, May 31st. They issued a “buy” rating and a $200.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $187.08.

Ascendis Pharma A/S Trading Up 19.9 %

Shares of ASND stock opened at $142.99 on Monday. The firm has a fifty day simple moving average of $132.45 and a 200-day simple moving average of $136.53. The company has a market capitalization of $8.33 billion, a PE ratio of -14.88 and a beta of 0.63. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors have recently made changes to their positions in ASND. Profund Advisors LLC lifted its stake in Ascendis Pharma A/S by 3.0% in the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after buying an additional 85 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 91 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Ascendis Pharma A/S by 52.0% in the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 102 shares during the period. Rhumbline Advisers boosted its holdings in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its stake in Ascendis Pharma A/S by 90.4% during the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.